gefitinib has been researched along with taxane in 4 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (taxane) | Trials (taxane) | Recent Studies (post-2010) (taxane) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,288 | 210 | 779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianco, AR; Biroccio, A; Borriello, G; Caputo, R; Ciardiello, F; Del Bufalo, D; Tortora, G; Zupi, G | 1 |
| Doihara, H; Fujita, T; Ishibe, Y; Kawasaki, K; Ogasawara, Y; Shien, T; Taira, N; Takabatake, D; Takahashi, H; Yoshitomi, S | 1 |
| du Bois, A; Gropp, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Meier, W; Pfisterer, J; Schmalfeldt, B; Sehouli, J; Stähle, A; Wagner, U | 1 |
| Hu, Q; Xie, B; Xu, Z; Zhang, W; Zhang, X; Zheng, J; Zhou, J | 1 |
1 trial(s) available for gefitinib and taxane
| Article | Year |
|---|---|
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Patient Compliance; Quinazolines; Tamoxifen; Taxoids | 2007 |
3 other study(ies) available for gefitinib and taxane
| Article | Year |
|---|---|
ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Taxoids; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2002 |
Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase; Gefitinib; Humans; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Rate; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 2007 |
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Topics: Biomarkers, Tumor; Bridged-Ring Compounds; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Mutation; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2018 |